MINDACT Trial (Microarray In Node-negative and 1-3 node-positive Disease may Avoid ChemoTherapy)
Adjuvant Chemotherapy Planning
MINDACT was an independent, phase III, prospective, randomized clinical trial sponsored by the European Organization for Research and Treatment of Cancer (EORTC-10041/BIG3-04). The goal of the study was to determine whether the MammaPrint test could be used to safely de-escalate clinical high risk patients with early stage breast cancer from chemotherapy treatment without compromising their outcomes.
The initial data were published in the New England Journal of Medicine in 2016 and demonstrated that clinically high risk, MammaPrint Low Risk patients could avoid chemotherapy without compromising their outcomes.1 Long-term data, with median follow-up approaching 9 years, were presented at ASCO 2020 confirming and expanding upon the 2016 findings.